The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Lilly’s diabetes and oncology franchises epitomize the effects of the pandemic on pharmaceutical sales. For much smaller companies, these effects were magnified.

Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.

As the first-quarter 2020 earnings season transitions from big pharma to the long tail of smaller biotech companies, the coronavirus pandemic-related dynamics of channel stocking and greatly diminished numbers of clinic visits have magnified effects at companies with single underperforming drugs.